Target Gene/Pathway(薬物標的遺伝子/パスウェイリスト)
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z other
| No. | KEGG PATHWAY * On map, Yellow: Drug target, Red: Disease-related |
KEGG GENES * | KEGG DRUG * | DrugBank | 指定難病告示番号 * |
| 1 | Adipocytokine signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 2 | African trypanosomiasis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 3 | AGE-RAGE signaling pathway in diabetic complications |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 4 | Allograft rejection |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 5 | Alzheimer disease |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
| 6 | Amoebiasis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 7 | Amphetamine addiction |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 8 | Amyotrophic lateral sclerosis (ALS) |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
| 9 | Antifolate resistance |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 10 | Antigen processing and presentation |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 11 | Apoptosis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 12 | Asthma |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 13 | Axon guidance |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 14 | B cell receptor signaling pathway |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 15 | C-type lectin receptor signaling pathway |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
| 16 | Calcium signaling pathway |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 17 | Cellular senescence |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 18 | cGMP-PKG signaling pathway |
1件: OPRD1 | D02095 | Naltrexone | 11件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 |
| D05113 | |||||
| 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 | ||
| 19 | Chagas disease (American trypanosomiasis) |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 20 | Cytokine-cytokine receptor interaction |
1件: CSF3R | D03235 | Filgrastim | 28件: 2, 6, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 85, 96, 113, 164, 283, 284, 285, 331 |
| 1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 | ||
| 1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
| 21 | Dilated cardiomyopathy (DCM) |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 22 | DNA replication |
2件: POLA1, POLA2 | D03546 | Clofarabine | 9件: 19, 20, 40, 46, 49, 60, 96, 234, 326 |
| 23 | Dopaminergic synapse |
3件: PPP3CA, PPP3CB, PPP3CC | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 24 | Drug metabolism - other enzymes |
1件: RRM1 | D03546 | Clofarabine | 9件: 19, 20, 40, 46, 49, 60, 96, 234, 326 |
| 25 | EGFR tyrosine kinase inhibitor resistance |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
| 26 | Epstein-Barr virus infection |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 27 | Estrogen signaling pathway |
1件: OPRM1 | D02095 | Naltrexone | 11件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 |
| D05113 | |||||
| 28 | Fc epsilon RI signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 29 | Fluid shear stress and atherosclerosis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 30 | Glucagon signaling pathway |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 31 | Glutamatergic synapse |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 32 | Glutathione metabolism |
1件: RRM1 | D03546 | Clofarabine | 9件: 19, 20, 40, 46, 49, 60, 96, 234, 326 |
| 33 | Graft-versus-host disease |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 34 | Hematopoietic cell lineage |
1件: CSF3R | D03235 | Filgrastim | 28件: 2, 6, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 85, 96, 113, 164, 283, 284, 285, 331 |
| 1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 | ||
| 1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
| 35 | Hepatitis B |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 36 | Hepatitis C |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 37 | Herpes simplex virus 1 infection |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 38 | HIF-1 signaling pathway |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
| 39 | Human cytomegalovirus infection |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
| 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 | ||
| 1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
| 40 | Human immunodeficiency virus 1 infection |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
| 41 | Human papillomavirus infection |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 42 | Human T-cell leukemia virus 1 infection |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
| 43 | Hypertrophic cardiomyopathy (HCM) |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 44 | IL-17 signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 45 | Inflammatory bowel disease (IBD) |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 46 | Influenza A |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 47 | Insulin resistance |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 48 | JAK-STAT signaling pathway |
1件: CSF3R | D03235 | Filgrastim | 28件: 2, 6, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 85, 96, 113, 164, 283, 284, 285, 331 |
| 1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 | ||
| 49 | Kaposi sarcoma-associated herpesvirus infection |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 50 | Legionellosis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 51 | Leishmaniasis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 52 | Long-term potentiation |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 53 | Malaria |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 54 | MAPK signaling pathway |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
| 55 | Metabolic pathways |
1件: DHODH | D00749 | Leflunomide | 10件: 11, 40, 46, 49, 53, 66, 162, 224, 271, 300 |
| 1件: RRM1 | D03546 | Clofarabine | 9件: 19, 20, 40, 46, 49, 60, 96, 234, 326 | ||
| 56 | Morphine addiction |
1件: OPRM1 | D02095 | Naltrexone | 11件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 |
| D05113 | |||||
| 57 | mTOR signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 58 | Natural killer cell mediated cytotoxicity |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
| 59 | Necroptosis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 60 | Neuroactive ligand-receptor interaction |
1件: NR3C1 | D00407 | Methylprednisolone | 36件: 2, 13, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 145, 164, 220, 222, 224, 271, 283, 284, 285, 296 |
| D00751 | |||||
| D00979 | |||||
| D05000 | |||||
| D05001 | |||||
| D05002 | |||||
| D00473 | Prednisone | 44件: 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 95, 96, 97, 113, 145, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 | |||
| D08416 | Prednisone acetate | 6件: 35, 40, 41, 49, 162, 224 | |||
| D00385 | Triamcinolone | 18件: 6, 10, 13, 35, 40, 41, 42, 43, 44, 45, 46, 56, 70, 90, 96, 97, 226, 298 | |||
| D00983 | |||||
| D00984 | |||||
| D00985 | |||||
| D06216 | |||||
| 3件: OPRD1, OPRK1, OPRM1 | D02095 | Naltrexone | 11件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 | ||
| D05113 | |||||
| 61 | NF-kappa B signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 62 | NOD-like receptor signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 63 | Non-alcoholic fatty liver disease (NAFLD) |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
| 1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
| 64 | Oocyte meiosis |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 65 | Osteoclast differentiation |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
| 66 | Oxytocin signaling pathway |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 67 | Pathogenic Escherichia coli infection |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 68 | Pathways in cancer |
1件: CSF3R | D03235 | Filgrastim | 28件: 2, 6, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 85, 96, 113, 164, 283, 284, 285, 331 |
| 1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 | ||
| 69 | PD-L1 expression and PD-1 checkpoint pathway in cancer |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 70 | Pertussis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 71 | PI3K-Akt signaling pathway |
1件: CSF3R | D03235 | Filgrastim | 28件: 2, 6, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 85, 96, 113, 164, 283, 284, 285, 331 |
| 1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 | ||
| 72 | Proteoglycans in cancer |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 73 | Purine metabolism |
1件: RRM1 | D03546 | Clofarabine | 9件: 19, 20, 40, 46, 49, 60, 96, 234, 326 |
| 74 | Pyrimidine metabolism |
1件: DHODH | D00749 | Leflunomide | 10件: 11, 40, 46, 49, 53, 66, 162, 224, 271, 300 |
| 1件: RRM1 | D03546 | Clofarabine | 9件: 19, 20, 40, 46, 49, 60, 96, 234, 326 | ||
| 75 | Renin secretion |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 76 | Rheumatoid arthritis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 77 | RIG-I-like receptor signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 78 | Shigellosis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 79 | Sphingolipid signaling pathway |
1件: OPRD1 | D02095 | Naltrexone | 11件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 |
| D05113 | |||||
| 1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
| 80 | Systemic lupus erythematosus |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 81 | T cell receptor signaling pathway |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
| 82 | TGF-beta signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 83 | Th1 and Th2 cell differentiation |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 84 | Th17 cell differentiation |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
| 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 | ||
| 85 | TNF signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 86 | Toll-like receptor signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 87 | Toxoplasmosis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 88 | Tuberculosis |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
| 89 | Type I diabetes mellitus |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 90 | Type II diabetes mellitus |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 91 | VEGF signaling pathway |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 92 | Viral protein interaction with cytokine and cytokine receptor |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
| 1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
| 93 | Wnt signaling pathway |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 94 | Yersinia infection |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |